Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually?
Metastatic urothelial carcinoma (mUC) is an aggressive malignancy with a dismal prognosis. Enfortumab vedotin (EV) is an antibody-drug conjugate consisting of an antibody targeting Nectin-4. This protein is highly expressed in UC cells. After binding, monomethyl auristatin E is released into cells,...
| Main Authors: | , , , |
|---|---|
| 格式: | 文件 |
| 语言: | English |
| 出版: |
Frontiers Media S.A.
2023-09-01
|
| 丛编: | Frontiers in Oncology |
| 主题: | |
| 在线阅读: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1254906/full |